following a full submission assessed under the end of life and orphan equivalent medicine process:
nivolumab (Opdivo®) is accepted for use within NHSScotland.
Indication under review: as monotherapy for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy.
In a phase III study, treatment with nivolumab significantly improved overall survival compared with taxane chemotherapy in patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Medicine details
- Medicine name:
- nivolumab (Opdivo)
- SMC ID:
- SMC2362
- Indication:
As monotherapy for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine and platinum-based combination chemotherapy
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 09 August 2021